MOTS-c is an experimental mitochondrial-derived peptide studied for metabolism, insulin sensitivity, and exercise-related signaling, but it is not FDA-approved for human use. Reported side effects include injection-site irritation, fatigue, headache, dizziness, nausea, insomnia, fever-like symptoms, and palpitations. Because there is no approved label, true side-effect rates and long-term safety are unknown 1, 2, 3.
Wondering if NAD+ is right for you? Take the 3-min clinical quiz.
See if you qualify →What are the most common MOTS-c peptide side effects?
MOTS-c side effects are not well measured because there is no FDA-approved MOTS-c drug and no large human safety program. Symptoms discussed in unverified reports include injection-site irritation, fatigue or low energy, headache, dizziness, nausea, sleep changes, fever-like symptoms, and palpitations; these reports should be treated as safety signals, not known rates.
MOTS-c is discussed because early research links it to mitochondrial stress signaling, AMPK activation, glucose handling, and exercise adaptation 1, 2. But benefit and risk have to be viewed together: the same metabolic pathways that make MOTS-c interesting may also overlap with symptoms such as fatigue, lightheadedness, or blood sugar changes.
Injection-site redness, swelling, or irritation
For any injected peptide, local reactions can happen because the skin and immune system respond to a needle, the solution, or contamination. Redness, swelling, itching, warmth, pain, or drainage should not be ignored, especially if symptoms spread or come with fever.
Fatigue, low energy, or temporary energy fluctuations
Fatigue is one of the main symptoms people search for with MOTS-c, but it has not been quantified in an FDA-reviewed MOTS-c label. MOTS-c has been studied for AMPK-related energy signaling, which is one reason fatigue is biologically plausible, but controlled human safety data are limited 1, 2.
Headache, dizziness, or lightheadedness
Headache and dizziness can overlap with dehydration, low food intake, sleep loss, anxiety, blood pressure changes, or blood sugar changes. Because MOTS-c is not an approved drug, clinicians do not have an FDA-vetted side-effect table to estimate how often these symptoms occur.
Nausea or digestive discomfort
Nausea and stomach discomfort appear in some unverified reports from people using experimental peptides, but MOTS-c does not have approved labeling that confirms a gastrointestinal side-effect rate. Persistent vomiting, severe belly pain, fainting, or signs of dehydration need medical care.
Insomnia, fever, or flu-like symptoms
Sleep disruption and flu-like symptoms can happen with many immune or injection-related reactions, but MOTS-c-specific rates are not established. Fever after an injection can also point to infection or contamination, which is one reason research-use-only products are risky outside regulated medical care.
Heart palpitations or increased heart rate
Palpitations mean feeling a racing, pounding, skipping, or irregular heartbeat. Palpitations and increased heart rate have not been quantified in an approved MOTS-c label; people with arrhythmias, heart disease, chest pain, fainting, or unexplained shortness of breath should not self-experiment with metabolic peptides.
| Symptom | Possible concern | When to seek care |
|---|---|---|
| Injection-site redness or swelling | Irritation, allergic reaction, or infection | If redness spreads, pain worsens, pus appears, or fever occurs |
| Fatigue or brain fog | Energy-stress signaling, sleep disruption, low intake, or blood sugar changes | If severe, persistent, paired with confusion, or affects safety |
| Dizziness or lightheadedness | Low blood sugar, low blood pressure, dehydration, or other causes | If fainting, chest pain, weakness, or confusion occurs |
| Nausea | Digestive irritation or systemic reaction | If vomiting is severe, dehydration develops, or belly pain is intense |
| Palpitations | Heart rhythm change, stimulant effect, anxiety, or another cardiac cause | Urgently if chest pain, fainting, shortness of breath, or sustained rapid heartbeat occurs |
What is MOTS-c, and why do people use it?
MOTS-c is a mitochondrial-derived peptide, meaning it is a small protein-like molecule connected to mitochondrial DNA. In early research, it has been linked to metabolism, glucose handling, and cellular stress responses, but no FDA-approved human use has been established 1, 2.
MOTS-c as a mitochondrial-derived peptide
Most genes that code for proteins sit in the cell nucleus. MOTS-c is unusual because it comes from a short open reading frame in mitochondrial DNA, which is why its full name is mitochondrial open reading frame of the 12S rRNA-c 1.
Mitochondria help cells make usable energy. They also send stress signals. Researchers study mitochondrial-derived peptides because they may act like messages between energy status, inflammation, and metabolism 2.
Why it is discussed for metabolism, insulin sensitivity, and exercise signaling
In a 2015 Cell Metabolism study, MOTS-c improved metabolic measures in mice exposed to a high-fat diet and activated AMPK-related pathways in cells 1. That is interesting science, but mouse and cell findings do not prove a safe or effective treatment in humans.
Human evidence is smaller and more indirect. For example, human exercise research has measured MOTS-c changes around physical activity and aging-related biology, but these studies do not establish MOTS-c as a prescription treatment for weight loss, diabetes, athletic performance, or longevity 3, 4. Individual results vary, and clinical benefits remain unproven.
What research shows versus what is still unproven in humans
- Animal evidence: MOTS-c has been studied in mice for metabolic stress, insulin sensitivity, and exercise-related signaling 1.
- Cell evidence: MOTS-c has been studied for AMPK activation and nuclear stress-response pathways 2.
- Human evidence: small studies connect MOTS-c biology with aging, exercise, and metabolic markers, but they do not prove clinical benefit 3, 4.
- Unproven uses: weight loss, longevity, fertility, athletic performance, and diabetes treatment remain investigational for MOTS-c.
Why might MOTS-c cause fatigue or brain fog?
Fatigue on MOTS-c may relate to energy balance, blood sugar changes, sleep disruption, or unrelated health issues. Because there is no approved MOTS-c label, there is no proven timeline for how long fatigue should last or how it should be managed.
Metabolic adaptation and AMPK signaling
AMP-activated protein kinase, or AMPK, is a cell energy sensor. When energy is low, AMPK helps shift cells toward fuel use and energy conservation; MOTS-c has been studied as an AMPK activator in experimental systems 1, 2.
That mechanism is why some people speculate about fatigue or a “hangover” feeling. But this remains a theory unless it is tested in controlled human studies with careful symptom tracking.
Blood sugar changes as a possible contributor
MOTS-c research has focused partly on glucose metabolism and insulin sensitivity 1. If a person is also using insulin, sulfonylureas, GLP-1 medicines, fasting, or eating very little, symptoms like shakiness, sweating, confusion, headache, and fatigue could overlap with low blood sugar. The American Diabetes Association notes that hypoglycemia can cause shakiness, sweating, confusion, and palpitations 9.
Why online theories about folate-cycle effects should be treated as unproven
Some online discussions claim MOTS-c fatigue comes from folate-cycle or methylation effects. At this point, those explanations should be treated as unproven for patient care unless supported by clinical studies that measure the pathway and symptoms in humans.
Can MOTS-c affect blood sugar or diabetes medications?
MOTS-c and blood sugar are closely linked in research, but that does not make MOTS-c a diabetes treatment. People with diabetes, hypoglycemia, or glucose-lowering medications need clinician oversight because symptoms can overlap and risks can be higher.
MOTS-c research on glucose handling and insulin sensitivity
The original MOTS-c metabolic studies reported improved insulin sensitivity and glucose-related measures in mice, along with AMPK pathway effects 1. Later research explored how MOTS-c may change with exercise and metabolic stress, but human treatment outcomes remain unproven 3.
Why people with diabetes, hypoglycemia, or glucose-lowering medications need clinician oversight
A person using insulin or another glucose-lowering medication may have a narrow safety margin. Any experimental compound that could affect appetite, food intake, insulin sensitivity, or exercise tolerance can make blood sugar harder to predict.
Symptoms that may overlap with low blood sugar
- Sweating, shaking, or feeling suddenly weak
- Fast heartbeat or palpitations
- Headache, dizziness, or blurred vision
- Confusion, irritability, or brain fog
- Nausea or feeling faint
If these symptoms occur in someone with diabetes or a history of low blood sugar, it is safer to treat them as medically important rather than assuming they are a normal peptide side effect 9.
Is MOTS-c safe for the heart?
MOTS-c heart safety is not established in large human trials. Palpitations, increased heart rate, chest symptoms, fainting, or shortness of breath should be taken seriously, especially in people with arrhythmias or cardiovascular disease.
Reported palpitations and increased heart rate
Palpitations are not specific to MOTS-c. They can come from anxiety, stimulants, dehydration, thyroid disease, low blood sugar, electrolyte problems, or heart rhythm disorders. The concern is that MOTS-c lacks an approved drug label, so clinicians do not have a complete adverse-event profile to rely on.
Why people with arrhythmias, cardiovascular disease, or unexplained chest symptoms should be cautious
People with atrial fibrillation, prior heart attack, heart failure, known arrhythmia, unexplained fainting, or chest pain should not self-experiment with metabolic peptides. A clinician can review medications, cardiac history, labs, and whether symptoms need urgent workup.
When urgent medical care is appropriate
- Chest pain, chest pressure, or pain spreading to the jaw, arm, or back
- Fainting or nearly fainting
- Shortness of breath at rest
- A sustained very fast or irregular heartbeat
- New weakness, confusion, or trouble speaking
Who should not take MOTS-c peptide?
People who should avoid self-use of MOTS-c include those who are pregnant, breastfeeding, trying to conceive, using fertility treatment, managing diabetes or hypoglycemia, living with heart rhythm disease, or competing under WADA rules. The main reason is simple: MOTS-c has limited human safety data and no approved human indication.
Pregnancy, breastfeeding, and fertility treatment considerations
MOTS-c is sometimes discussed online for fertility or ovarian aging, but this is not an approved use. Pregnancy and fertility care require a higher safety bar because embryo development, hormone treatment, and fetal exposure can change the risk calculation.
Diabetes, hypoglycemia, or use of glucose-lowering medication
Because MOTS-c is studied in glucose metabolism, people with diabetes or a history of low blood sugar need medical review before considering any experimental peptide 1, 9. This is especially true for people using insulin, sulfonylureas, GLP-1 medicines, or multiple metabolic medications.
Heart rhythm issues or significant cardiovascular disease
People with arrhythmias or cardiovascular disease should be cautious with any compound linked to metabolic or exercise signaling. Palpitations or dizziness may be harmless in some cases, but they can also be signs of a heart rhythm issue.
Competitive athletes subject to WADA rules
The World Anti-Doping Agency prohibits MOTS-c as an AMPK activator under the metabolic modulators category 5. USADA also warns athletes that MOTS-c is prohibited and may appear in products sold as peptides or performance aids 6.
People considering research-use-only products
Products labeled “research use only” are not the same as prescribed medication. They may not meet the same standards for identity, sterility, potency, contaminants, storage, or patient-specific medical review.
Is MOTS-c FDA-approved or legally available?
MOTS-c has no FDA-approved drug for human use, and there is no FDA-approved brand name or approved generic drug name. On July 23-24, 2026, FDA’s Pharmacy Compounding Advisory Committee recommended MOTS-c for inclusion on the 503A Bulks List, but FDA’s final determination is pending 7, 8.
No FDA-approved MOTS-c drug for human use
An FDA-approved drug has an approved label, manufacturing review, indication, dose framework, contraindications, and adverse-event information. MOTS-c does not have that framework for patients.
Why research-use-only products are not the same as prescribed medication
A research-use-only label means a product is not intended for human treatment. It does not give a clinician a reliable patient-specific pathway for screening, follow-up, side-effect management, or drug-interaction review.
What patients should ask a licensed clinician before considering any experimental peptide
- What human evidence exists for this specific peptide and goal?
- What are the known and unknown risks for my health history?
- Could it interact with my medications or supplements?
- How would side effects be monitored?
- Is the source a licensed pharmacy pathway or a research-use-only seller?
How does MOTS-c compare with peptides Chia does offer?
Chia does not currently offer MOTS-c. When patients come to us interested in longevity or metabolic support, our role is to separate experimental claims from clinician-reviewed options we can actually evaluate online, prescribe when appropriate, and source through state-licensed 503A pharmacies.
At Chia, current longevity-related options include NAD+ as an injection or nasal spray, glutathione as an injection or nasal spray, and sermorelin as an injection, nasal spray, or tablets. We also offer protocols such as Foundation Longevity, Weight + Energy, and Weight + Muscle for patients whose health history and goals fit those pathways. Compounded medications are not FDA-approved and require licensed-provider review.
| Option | What it is | Forms at Chia | Current Chia pricing | Important safety note |
|---|---|---|---|---|
| MOTS-c | Experimental mitochondrial-derived peptide studied for AMPK and metabolism signaling | Not offered by Chia | Not available through Chia | No FDA-approved human use; long-term human safety data are limited |
| NAD+ | A molecule involved in cellular redox and energy biology | Injection or nasal spray | Nasal spray plans currently start at $119/mo; injection plans currently start at $179/mo | Requires licensed-provider review; compounded medications are not FDA-approved |
| Glutathione | An antioxidant molecule involved in redox balance | Injection or nasal spray | Injection plans currently start at $179/mo | Requires licensed-provider review; compounded medications are not FDA-approved |
| Sermorelin | A growth-hormone-releasing hormone analog used in clinician-guided longevity care | Injection, nasal spray, or tablets | Injection plans currently start at $179/mo | Requires licensed-provider review; compounded medications are not FDA-approved |
| Foundation Longevity | Sermorelin Injection + NAD+ Injection + Glutathione Injection | Protocol | Plans currently start at $399/mo | Prescription requires medical evaluation and is not guaranteed |
The difference is not that every offered treatment is risk-free. It is that a licensed provider reviews your health history, medications, goals, and contraindications before prescribing, and medications are compounded by US state-licensed 503A pharmacies when clinically appropriate.
How can patients reduce risk when researching peptides?
The safer peptide path is licensed care, not self-experimentation. That means clinician evaluation, medication review, appropriate follow-up, and pharmacy sourcing rather than research-use-only products.
Avoid products labeled for research use only
Research-use-only products are not made or labeled for patient treatment. The risks include wrong identity, wrong strength, contamination, poor storage, and no clinician available if side effects occur.
Look for clinician evaluation, prescription oversight, and licensed pharmacy sourcing
For treatments Chia offers, the process starts with a 100% online health questionnaire. A licensed US provider reviews it and prescribes only when clinically appropriate; a prescription is never guaranteed. Medications are compounded in the US by state-licensed 503A pharmacies and shipped to the patient’s door.
Use lab testing and follow-up only when clinically appropriate
Some patients need labs or closer follow-up because of medical history, symptoms, or medication risks. Others may not. The point is not to order every test; it is to match monitoring to the person.
Do not self-dose or combine peptides without medical guidance
Peptide stacking can raise risk because side effects can overlap. For example, fatigue, headache, dizziness, nausea, sleep disruption, and heart symptoms may have more than one cause when several compounds are used together.
If you are considering a treatment Chia does offer, you can start with an online eligibility review. A licensed provider reviews your health history and goals before deciding whether any prescription is appropriate; Chia does not offer MOTS-c.
FAQ: MOTS-c peptide side effects
People who are pregnant, breastfeeding, trying to conceive, using fertility treatment, managing diabetes or hypoglycemia, taking glucose-lowering medication, living with arrhythmias or significant heart disease, or competing under WADA rules should not self-use MOTS-c. It is experimental and not FDA-approved for human use.
There is no FDA-approved MOTS-c dosing schedule or treatment duration. Any website giving a standard cycle is not using an approved human label. A licensed clinician should review the evidence, risks, and alternatives before any experimental peptide is considered.
Fatigue may relate to sleep disruption, low food intake, blood sugar changes, dehydration, injection reaction, or metabolic signaling. MOTS-c is studied for AMPK and energy-stress pathways, but human data do not yet prove why some people feel tired.
Heart safety is not established in large human trials. Palpitations, chest pain, fainting, shortness of breath, or a sustained fast or irregular heartbeat should be treated as medically important, especially in people with arrhythmias or cardiovascular disease.
It is not proven that MOTS-c causes low blood sugar in humans, but MOTS-c is studied for glucose handling and insulin sensitivity. Symptoms such as sweating, shaking, dizziness, fast heartbeat, headache, or confusion can overlap with hypoglycemia and should be taken seriously.
Yes. WADA lists MOTS-c as a prohibited metabolic modulator because it is an AMPK activator. Competitive athletes should verify status with GlobalDRO, USADA, or their sport governing body before using any peptide or supplement.
No. MOTS-c has no FDA-approved drug for human use, no approved brand name, and no approved human dosing standard. PCAC recommended MOTS-c for the 503A Bulks List in July 2026, but FDA’s final determination is pending.
No. Chia does not currently offer MOTS-c. Chia does offer other clinician-reviewed longevity treatments, including NAD+, glutathione, and sermorelin, when a licensed provider determines they are clinically appropriate.
References
- 1.Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, Kim SJ, Mehta H, Hevener AL, de Cabo R, Cohen P. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015.
- 2.Kim KH, Son JM, Benayoun BA, Lee C. The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress. Cell Metabolism. 2018.
- 3.Reynolds JC, Lai RW, Woodhead JST, Joly JH, Mitchell CJ, Cameron-Smith D, Lu R, Cohen P, Graham NA, Benayoun BA, Lee C. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications. 2021.
- 4.Fuku N, Pareja-Galeano H, Zempo H, Alis R, Arai Y, Lucia A, Hirose N. The mitochondrial-derived peptide MOTS-c: a player in exceptional longevity? Aging Cell. 2015.
- 5.World Anti-Doping Agency. The World Anti-Doping Code International Standard: Prohibited List 2026. World Anti-Doping Agency. 2026.
- 6.United States Anti-Doping Agency. Athlete Advisory: MOTS-c is prohibited in sport. United States Anti-Doping Agency. 2024.
- 7.U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee Meeting Materials, July 23-24, 2026. U.S. Food and Drug Administration. 2026.
- 8.Drug Topics. FDA advisory committee recommends six of seven nominated peptides for 503A Bulks List, including MOTS-c. Drug Topics. 2026.
- 9.American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes—2026: Glycemic Goals and Hypoglycemia. Diabetes Care. 2026.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if NAD+ is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
